Navigation Links
ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting
Date:10/20/2008

- Phase III data highlight the benefits of ACTEMRA for rheumatoid arthritis -

NUTLEY, N.J., Oct. 20 /PRNewswire/ -- Roche today announced that a total of 15 abstracts involving its investigational rheumatoid arthritis (RA) treatment ACTEMRA(R) (tocilizumab) have been accepted for presentation at the 2008 American College of Rheumatology (ACR) Annual Scientific Meeting, which will take place October 24-29 in San Francisco. These studies evaluate ACTEMRA, a novel treatment targeting interleukin-6 (IL-6) receptors, in patients with moderately to severely active RA.

Platform Presentations/Poster Sessions

-- October 27, 2:45 pm - 3:00 pm PDT, Room 307 [Oral Presentation during

the RA Treatment: Biologic Efficacy RCT's session],

"Tocilizumab Rapidly and Significantly Improves Outcomes in

Patients with Rheumatoid Arthritis Who Have Inadequate Response to TNF

Antagonists" (Presenter: Paul Emery, M.D.)

-- October 27, 3:00 pm - 3:15 pm PDT, Room 307 [Oral Presentation during

the RA Treatment: Biologic Efficacy RCT's session], "The

AMBITION Study: Superiority of Tocilizumab vs. Methotrexate Monotherapy

in Patients with Rheumatoid Arthritis" (Presenter: Graeme Jones,

M.D.)

-- October 28, 3:15 pm - 3:30 pm PDT, Room 307 [Oral Presentation during

the ACR Business Meeting and Late-Breaking Abstracts session],

"Tocilizumab Inhibits Structural Joint Damage in RA Patients with

an Inadequate Response to Methotrexate: The LITHE Study"

(Presenter: Joel M. Kremer, M.D.)

-- There are 12 additional posters and abstracts highlighting results from

the extensive multi-national ACTEMRA clinical development program, which

included more than 4,000 patients in 41 countries, including the U.S.

About ACTEMRA (tocilizumab)

ACTEMRA is the first humanized interleukin-6 (IL-6) receptor-inhibiting
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Five New Clinical Studies Show Value of Masimo PVI & PI
2. NIST studies how new helium ion microscope measures up
3. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
4. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
5. OpenClinica EDC Solution Deployed for Retina Implant Studies
6. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
7. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
8. Studies Show USGI Medicals EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass
9. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
10. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
11. Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... periods ended June 30, 2015. Biorem,s complete second quarter financial statements ... FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended , Six ... , 2015 , 2014 Revenue , ... 4,433 Gross profit , 1,656 , 56 ...
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
(Date:8/26/2015)... (PRWEB) , ... August 26, 2015 , ... ... is increasing its investment in the development and manufacture of highly valued cardiac ... The company’s scientific team's extensive expertise with protein chemistry has led to the ...
(Date:8/26/2015)... -- China Cord Blood Corporation (NYSE: CO ) ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has been informed that Magnum Opus 2 ... Mr. Yuen Kam, chairman of the board of directors ... "Shares") of  Excellent China Healthcare Investment Limited ("KKR SPV") ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... Systems, Inc., a technology leader in developing novel chip-on-catheter ... a new 510(k) clearance for its Third Eye(R) Retroscope(R) ... cancerous and pre-cancerous polyps in the colon. This ... the FDA to enhance polyp detection when used in ...
... college-aged women expert guidance in career, financial planning ... young women enter the "real world" expecting that ... it comes to their careers, finances and relationships. ... often happens -- a looming problem especially in ...
... Feb. 17 GeneGo, Inc., the leading systems ... licensed 250 manually curated pathway maps from GeneGo, ... Available at www.millipore.com/pathways , the tool links ... well as relevant bioinformatics content to related biological ...
Cached Biology Technology:Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 2Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 3Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 4Helping Young Women Succeed in Today's Unpredictable World 2Helping Young Women Succeed in Today's Unpredictable World 3Helping Young Women Succeed in Today's Unpredictable World 4Millipore Launches an Interactive Biological Pathway Tool Using GeneGo's Manually Curated Pathway Maps 2Millipore Launches an Interactive Biological Pathway Tool Using GeneGo's Manually Curated Pathway Maps 3
(Date:8/4/2015)... 2015  AMRI (NASDAQ: AMRI ) today reported financial and ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 % ... a $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial ...
(Date:7/31/2015)... juli 2015 Den 10. internationale konference om ... den 22. - 25. oktober i Shenzhen ... 10-års fødselsdag i år. Siden starten i 2006 er ... på ,omik,-feltet, og er en af de mest dynamiske, ... fokuserer på nylige gennembrud og fremskridt inden for ,omik,-forskning, ...
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... National Institutes of Health has awarded 23 grants for ... five years. The projects will focus on determining the ... medicine. The awards are part of the ... 2000 with the main goal of developing highly efficient, ...
... the millions of Americans with high blood pressure, more help ... published in the October 2010 print issue of The ... called P450, metabolizes arachidonic acid in our blood vessel walls ... (EET)which in mice, turns off genes responsible for vascular inflammation ...
... Arizona State University has been awarded a $7.7 million ... of General Medical Sciences, part of the National Institutes of ... a key role in protection against infectious diseases. As ... Chemistry and Biochemistry in the College of Liberal Arts and ...
Cached Biology News:NIH grants will advance studies of the form and function of proteins 2NIH grants will advance studies of the form and function of proteins 3Scientists discover a new way our bodies control blood pressure: the P450-EET system 2NIH funds center at Arizona State to battle infectious diseases 2NIH funds center at Arizona State to battle infectious diseases 3
... thermostable DNA polymerase obtained by high level ... in E. coli, Concentration: 5U/ul, Applications: Standard ... Scientific, the world leader in serving science. ... the world healthier, cleaner and safer by ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... is a thermostable DNA polymerase derived ... at temperatures above 70°C, it was ... PCR and remains the predominant enzyme ... an intrinsic 5'?3' structure-dependent exonuclease activity, ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Biology Products: